Xie Yan, Bowe Benjamin, Li Tingting, Xian Hong, Yan Yan, Al-Aly Ziyad
Clinical Epidemiology Center, Research and Education Service, VA Saint Louis Health Care System, Saint Louis, Missouri, USA.
Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.
BMJ Open. 2017 Jul 4;7(6):e015735. doi: 10.1136/bmjopen-2016-015735.
Proton pump inhibitors (PPIs) are widely used, and their use is associated with increased risk of adverse events. However, whether PPI use is associated with excess risk of death is unknown. We aimed to examine the association between PPI use and risk of all-cause mortality.
Longitudinal observational cohort study.
US Department of Veterans Affairs.
Primary cohort of new users of PPI or histamine H2 receptor antagonists (H2 blockers) (n=349 312); additional cohorts included PPI versus no PPI (n=3 288 092) and PPI versus no PPI and no H2 blockers (n=2 887 030).
Risk of death.
Over a median follow-up of 5.71 years (IQR 5.11-6.37), PPI use was associated with increased risk of death compared with H2 blockers use (HR 1.25, CI 1.23 to 1.28). Risk of death associated with PPI use was higher in analyses adjusted for high-dimensional propensity score (HR 1.16, CI 1.13 to 1.18), in two-stage residual inclusion estimation (HR 1.21, CI 1.16 to 1.26) and in 1:1 time-dependent propensity score-matched cohort (HR 1.34, CI 1.29 to 1.39). The risk of death was increased when considering PPI use versus no PPI (HR 1.15, CI 1.14 to 1.15), and PPI use versus no PPI and no H2 blockers (HR 1.23, CI 1.22 to 1.24). Risk of death associated with PPI use was increased among participants without gastrointestinal conditions: PPI versus H2 blockers (HR 1.24, CI 1.21 to 1.27), PPI use versus no PPI (HR 1.19, CI 1.18 to 1.20) and PPI use versus no PPI and no H2 blockers (HR 1.22, CI 1.21 to 1.23). Among new PPI users, there was a graded association between the duration of exposure and the risk of death.
The results suggest excess risk of death among PPI users; risk is also increased among those without gastrointestinal conditions and with prolonged duration of use. Limiting PPI use and duration to instances where it is medically indicated may be warranted.
质子泵抑制剂(PPIs)被广泛使用,其使用与不良事件风险增加相关。然而,使用PPIs是否与死亡风险增加相关尚不清楚。我们旨在研究PPIs使用与全因死亡率风险之间的关联。
纵向观察性队列研究。
美国退伍军人事务部。
PPIs或组胺H2受体拮抗剂(H2阻滞剂)新使用者的主要队列(n = 349312);其他队列包括使用PPIs与未使用PPIs(n = 3288092)以及使用PPIs与未使用PPIs和未使用H2阻滞剂(n = 2887030)。
死亡风险。
在中位随访5.71年(四分位间距5.11 - 6.37)期间,与使用H2阻滞剂相比,使用PPIs与死亡风险增加相关(风险比1.25,95%置信区间1.23至1.28)。在根据高维倾向评分调整的分析中(风险比1.16,95%置信区间1.13至1.18)、在两阶段残差纳入估计中(风险比1.21,95%置信区间1.16至1.26)以及在1:1时间依赖性倾向评分匹配队列中(风险比1.34,95%置信区间1.29至1.39),与使用PPIs相关的死亡风险更高。考虑使用PPIs与未使用PPIs时死亡风险增加(风险比1.15,95%置信区间1.14至1.15),以及使用PPIs与未使用PPIs和未使用H2阻滞剂时死亡风险增加(风险比1.23,95%置信区间1.22至1.24)。在没有胃肠道疾病的参与者中,与使用PPIs相关的死亡风险增加:PPIs与H2阻滞剂相比(风险比1.24,95%置信区间1.21至1.27),使用PPIs与未使用PPIs相比(风险比1.19,95%置信区间1.18至1.20),以及使用PPIs与未使用PPIs和未使用H2阻滞剂相比(风险比1.22,95%置信区间1.21至1.23)。在新的PPIs使用者中,暴露持续时间与死亡风险之间存在分级关联。
结果表明PPIs使用者存在额外的死亡风险;在没有胃肠道疾病且使用时间延长的人群中风险也会增加。限制PPIs的使用和持续时间至医学指征明确的情况可能是必要的。